AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 22 min read$EVAX

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.

Original reporting
globenewswire.com
Published Oct 2, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The disclosed data provide the first detailed immunogenicity read‑out beyond tumor‑specific T‑cell responses, which could materially affect EVAX's valuation.

02

Market read

New trial data are a primary catalyst for EVAX, with potential spill‑over to the broader AI‑immunotherapy sector.

03

What to watch

Regulatory pathway uncertainties and the need for larger pivotal trials may limit near‑term upside.

Relevance 8/10Novelty 8/10Timing: upcoming conference presentation (Nov 6‑7 2026)

Background

Evaxion A/S (NASDAQ: EVAX) is a clinical‑stage TechBio company developing AI‑designed cancer vaccines. The company announced that new immune data from its phase‑2 EVX‑01 trial will be presented at the Society for Immunotherapy of Cancer meeting in November.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion will present new phase‑2 immune data for its personalized cancer vaccine EVX‑01 at the SITC 2026 Annual Meeting.

Expected impact

likely upward pressure as market prices in the new efficacy data.

Evidence & confidence

Phase‑2 data are material for a clinical‑stage biotech; fresh immunogenicity results often trigger price rallies.

Market effects

Sector

strengthens the AI‑driven immunotherapy niche and may boost peer biotech valuations.

Regional

European biotech investors may see increased interest in AI‑based vaccine platforms.

Global

adds credibility to AI‑immunology approaches, potentially influencing global biotech funding trends.

Counterpoint

What could challenge this read

If the data are not as robust as presented, the hype could reverse, leading to a sell‑off.

Key entities

  • company
    Evaxion A/S

    Clinical‑stage biotech developing AI‑designed immunotherapies.

  • company
    Merck & Co., Inc.

    Provider of pembrolizumab (Keytruda) used in combination with EVX‑01.

Read at source← All news

Related articles

OCT 23
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de3 min
OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min
OCT 19
$EVAXHighAI 8/10

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

investing.com2 min